BIA Separations, a biochromatography development and manufacturing company, is collaborating with AveXis, a Novartis company, to enhance the commercial purification process for its gene therapy pipeline, beginning with Zolgensma (onasemnogene abeparvovec-xioi), the first U.S. FDA-approved gene therapy indicated for the treatment of pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.   Zolgensma is a one-time infusion that provides a functional copy of the hu...